WST
West Pharmaceutical Services, Inc.
WST's fundamentals are strong: its operating margin rose 3 points to 23% and revenue grew 13%. At 46x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth.
WST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
WST's revenue, profitability, cash flow and balance sheet are all currently healthy.
WST PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $314 | -24% |
| Forward | 41x | $411 | — |
| Current | 46x | $411 | — |
| Fair | 47x | $417 | +1.3% |
| Expensive | 61x | $544 | +32% |
Historical ranges are pointers, not guarantees.
WST's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 41x next year's earnings, in its cheap range.
WST Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for WST, with profitability improving.
WST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.04 | +13% |
| Q3 2026 | $8.91 | +32% |
| Q2 2026 | $7.81 | +17% |
| Q1 2026 | $7.48 | +17% |
| Q4 2025 | $6.79 | +1.5% |
| Q3 2025 | $6.75 | +0.1% |
| Q2 2025 | $6.68 | -5% |
| Q1 2025 | $6.37 | -16% |
| Q4 2024 | $6.69 | -15% |
WST earned $8.91 per share over the past year, up 32% from the year before.
WST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $874.5M | +8.7% |
| Q2 2026 | $872.3M | +14% |
| Q1 2026 | $844.9M | +21% |
| Q4 2025 | $805M | +7.5% |
| Q3 2025 | $804.6M | +7.7% |
| Q2 2025 | $766.5M | +9.2% |
| Q1 2025 | $698M | +0.4% |
| Q4 2024 | $748.8M | +2.3% |
WST's revenue has grown year over year for eight quarters in a row: $875M last quarter, up 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +9.8 points |
| Q2 2026 | 21% | +0.5 points |
| Q1 2026 | 21% | +5.6 points |
| Q4 2025 | 19% | -1.9 points |
| Q3 2025 | 21% | -0.8 points |
| Q2 2025 | 20% | +2.1 points |
| Q1 2025 | 15% | -2.3 points |
| Q4 2024 | 21% | -0.7 points |
WST's operating margin was 31% last quarter, up 9.8 points from the same quarter a year ago, near the top of its range since 2019.
WST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $150.4M | +12% |
| Q2 2026 | $80.8M | -21% |
| Q1 2026 | $47.2M | -19% |
| Q4 2025 | $175M | +105% |
| Q3 2025 | $133.9M | +36% |
| Q2 2025 | $101.9M | +57% |
| Q1 2025 | $58.1M | +111% |
| Q4 2024 | $85.2M | -35% |
WST's free cash flow has been positive every quarter for seven years: $453M over the past year, up 20% from the year before.
WST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -500K shares |
| 1 year | -2.5% | -1.8M shares |
| 3 years | -6% | -4.5M shares |
| 5 years | -6.8% | -5.2M shares |
| Available history | -6.1% | -4.6M shares |
WST has 71M diluted shares, down 2.5% from a year ago, with $685M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $231M |
| Q2 2026 | $156.7M |
| Q1 2026 | $297.6M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $500,000 |
| Q1 2025 | $133.5M |
| Q4 2024 | $54.4M |
WST spent $685M buying back its own shares over the past year, about four times what it spent the year before.
WST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
WST has more cash than debt.
WST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.6 | Neutral |
| Stochastic | 71.9 | Neutral |
WST's weekly RSI is 70 (neutral) and its Stochastic is 72 (neutral).
WST PE vs Healthcare Sector
| Metric | WST | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 47 | 29 | 18 pts above |
WST is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
WST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $387.7 | 6.1% above |
| 20 week MA | $364.5 | 13% above |
| 50 week MA | $312.1 | 32% above |
| 100 week MA | $282.5 | 46% above |
| 200 week MA | $313.1 | 31% above |
WST has climbed back above all five of its weekly moving averages, and it's now 31% above its 200-week average.
WST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $150.8 | $283.0 | +88% |
| 2021 | $283.0 | $459.8 | +63% |
| 2022 | $459.8 | $235.1 | -49% |
| 2023 | $235.1 | $352.1 | +50% |
| 2024 | $352.1 | $333.2 | -5.4% |
| 2025 | $333.2 | $274.3 | -18% |
| 2026 YTD | $274.3 | $411.3 | +50% |
WST is up 50% so far in 2026, after finishing lower in three of the previous six years.